Swiss Biotechnology Company Anokion SA Achieves Major Acquisition and Funding, Providing Runway for Multiple Emerging Autoimmune Therapies

Swiss Biotechnology Company Anokion SA Achieves Major Acquisition and Funding, Providing Runway for Multiple Emerging Autoimmune Therapies

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the acquisition of Kanyos Bio, Inc. and the completion of a $40 million Series B financing. Anokion has come a long way, according to...

Pin It on Pinterest